Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis

Interferon‐α2 reduces elevated blood cell counts and splenomegaly in patients with myeloproliferative neoplasms (MPN) and may restore polyclonal hematopoiesis. Its use is limited by inflammation‐mediated toxicity, leading to treatment discontinuation in 10‐30% of patients. Ruxolitinib, a potent anti...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Autores principales: Mikkelsen, Stine Ulrik, Kjær, Lasse, Bjørn, Mads Emil, Knudsen, Trine Alma, Sørensen, Anders Lindholm, Andersen, Christen Bertel Lykkegaard, Bjerrum, Ole Weis, Brochmann, Nana, Fassi, Daniel El, Kruse, Torben A., Larsen, Thomas Stauffer, Mourits‐Andersen, Hans Torben, Nielsen, Claus Henrik, Pallisgaard, Niels, Thomassen, Mads, Skov, Vibe, Hasselbalch, Hans Carl
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6089176/
https://ncbi.nlm.nih.gov/pubmed/29932310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1619
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares